A Non-interventional, multicentre study to see prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in India
Not Applicable
Completed
- Conditions
- Health Condition 1: null- ovarian, primary peritoneal and fallopian tube cancer patients
- Registration Number
- CTRI/2018/08/015338
- Lead Sponsor
- AstraZeneca Pharma India Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients who provide written informed consent
2. Female � 18 years of age
3. Previously or newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer patients.
Exclusion Criteria
1. Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study
2. Patient participating in any other clinical study/ trial.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method